News | May 08, 2007

Newly Formed Aeon Bioscience Jumps into DES, Thrombosis Fray

May 9 — Brookwood Pharmaceuticals, Inc. and Targeted Technology Ventures LLC have announced the creation of a collaborative joint venture — Aeon Bioscience, Inc. — a company that will work to develop a new drug-eluting stent to overcome the current concerns of late stent thrombosis (LST) or blood clot formation at or near the site of the stent and vessel closure due to formation of scar tissue, known as restenosis.

"The drug-eluting stent (DES) market suffered a setback in September 2006 when, during the World Congress of Cardiology meeting held in Barcelona, Spain, data was presented identifying a concern over the long term safety of DES, specifically LST," said Christopher E. Banas, principal, Targeted Technology, who will serve as CEO of Aeon. "This safety issue provides an immediate need to develop a solution to the LST problem. As a result, Aeon will focus on the development of a more effective polymeric coating in order to improve the safety profile of DES. This will ultimately result in an improvement in the quality of life for patients suffering from cardiovascular disease."

Aeon Bioscience will be headquartered in Birmingham, AL.

The combined strengths of the two parent companies give Aeon a strong development team with a proven track record in biodegradable materials, drug delivery, vascular stent engineering, clinical testing and regulatory registrations. Brookwood and Targeted Technology also bring strong skills in management of intellectual property portfolios and access to recognized scientific and medical leaders. Additional collaborators will be added as Aeon's technology platforms make progress.

"Aeon Bioscience is uniquely positioned in the race to develop new drug-eluting polymers with the biocompatibility and biological performance necessary to meet the stringent demands of the next generation of coronary stents and cardiovascular implants," said Dr. Paul Castella, principal, Targeted Technology, who will serve as Aeon's Chief Business Officer.

For more information visit www.brookwoodpharma.com.

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init